Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
Bastia E, Toris C, Bukowski JM, Brambilla S, Galli C, Almirante N, Bergamini MVW, Lucarini L, Navratil T, Impagnatiello F. Bastia E, et al. Among authors: bergamini mvw. J Ocul Pharmacol Ther. 2021 May;37(4):215-222. doi: 10.1089/jop.2020.0126. Epub 2021 Feb 15. J Ocul Pharmacol Ther. 2021. PMID: 33595367
NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs.
Bastia E, Toris CB, Brambilla S, Galli C, Almirante N, Bergamini MVW, Masini E, Sgambellone S, Unser AM, Ahmed F, Torrejon KY, Navratil T, Impagnatiello F. Bastia E, et al. Among authors: bergamini mvw. Invest Ophthalmol Vis Sci. 2021 Mar 1;62(3):17. doi: 10.1167/iovs.62.3.17. Invest Ophthalmol Vis Sci. 2021. PMID: 33704360 Free PMC article.
Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.
Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry T, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MV, Robertson S, Weiner AL, Sallee VL. Hellberg MR, et al. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S13-33. doi: 10.1016/s0039-6257(02)00293-x. Surv Ophthalmol. 2002. PMID: 12204698
Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MV, Mallick S; Travatan Dosing Aid Study Group. Flowers B, et al. Clin Ther. 2006 Nov;28(11):1803-11. doi: 10.1016/j.clinthera.2006.11.001. Clin Ther. 2006. PMID: 17213000 Clinical Trial.
A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
Hughes BA, Bacharach J, Craven ER, Kaback MB, Mallick S, Landry TA, Bergamini MV. Hughes BA, et al. J Glaucoma. 2005 Oct;14(5):392-9. doi: 10.1097/01.ijg.0000176935.08392.14. J Glaucoma. 2005. PMID: 16148589 Clinical Trial.
31 results